Imexpharm Corporation

As of June 30, 2026, Imexpharm Corporation carries a market capitalization of 6.35T, placing it among publicly traded companies globally. Its enterprise value stands at 6.04T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Imexpharm Corporation's next confirmed earnings release is scheduled for December 2, 2026.

As of June 30, 2026, Imexpharm Corporation has 154.01M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Imexpharm Corporation maintains a current ratio of 3.36, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Imexpharm Corporation recorded 72.45B in income tax expense.

As of the close on October 22, 2026, Imexpharm Corporation's stock has declined approximately 28.44% over the past 52 weeks. The 50-day moving average sits at 37,230.00, while the 200-day moving average is 45,879.50.

As of June 30, 2026, Imexpharm Corporation holds 503.49B in cash and equivalents against 195.18B in total debt, resulting in a net debt position of 38.36B. Total book value stands at 2.34T, with working capital of 1.18T providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Imexpharm Corporation's most recent stock split took place on September 17, 2024 with a 1:2 split ratio.